Objectives: The aim of the study was to estimate acute and late complications of radiation therapy in primary invasive vaginal carcinoma (PIVC) patients. 
Introduction
Radiation therapy is the treatment of choice for most of the primary invasive vaginal carcinoma (PIVC) patients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Of the essential importance is intravaginal treatment. The source of ionizing radiation in intracavitary brachytherapy is radium (Ra-226) (rarely used nowadays) and afterloaded caesium (Cs-137) or iridium ; interstitial brachytherapy is performed by means of permanent implants of radioactive gold or iodine (I-125), and temporary implants containing radioactive iridium . Both brachytherapy modalities are combined for part of the patients. In cases of vaginal vault involvement additional intrauterine applicator is used [6, [8] [9] [10] [11] [12] [13] [14] [15] [16] . Generally, PIVC patients are advised low-dose rate (LDR, 0,4-2Gy/h) treatment and rarely medium-dose rate treatment (MDR, 2Gy -12Gy/h). In recent years, a growing number of institutions uses iridium sources of a high-dose rate (HDR, over 12Gy/h). For most of the patients intravaginal brachytherapy is supplemented with external radiation therapy [6, [16] [17] [18] [19] . Selected non-advanced PIVC patients with small (up to 0.5 cm) superficial neoplastic lesions may be treated with brachytherapy alone [6, 10, 11, 16, 18, 19] .
Objectives
The aim of the study was the analysis of acute and late complications of radiation therapy in PIVC patients. There are many controversies on the subject in the literature and their main reasons include rare occurrence of PIVC, differences in clinical profile and radiotherapy techniques advised in analyzed groups of patients, diverse type and severity assessment scales of the complications [6, 15, 17, [19] [20] [21] [22] [23] [24] [25] .
Material and methods
The detailed analysis was performed for the group of 152 PIVC patients given radical radiotherapy in the Krakow Branch of Centre of Oncology (COOK) during the 1967-2005 period.
Demographic, clinical and histopathological characteristics of the investigated group have been presented in detail in earlier work, "Prognostic factors for vaginal carcinoma patients". Total 152 100.0
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all of them had stage I 0 PIVC and the primary tumour did not exceed 0.5 cm in thickness and 2 cm in its largest dimension. The treatment was performed using vaginal colpostat (2 applicators along vagina axis with 2 additional dome applicators in cases of upper vagina involvement). Total radiation dose to primary tumor calculated at 0.5cm distance from vaginal mucosa was 65-70 Gy; vaginal mucosa received dose of 95-100 Gy. Remaining 14 (9.2%) patients in stage I 0 PIVC with primary tumour exceeding 0.5 cm thickness were additionally given external radiation therapy involving whole pelvis minor irradiation to 50 Gy in 25 fractions within 5-week-period.
All of the 91 patients with stage II 0 and III 0 PIVC were treated with the combination of intracavitary brachytherapy and external radiotherapy. Intracavitary brachytherapy dose to infiltration base was 65-70Gy. Dose to Manchester A points varied from 44 to 62Gy (mean value of 52Gy) with the overall irradiation time of 72 up to 132 hours, most commonly within 96-120 hours range. Rectal mucosa dose received due to intracavitary brachytherapy was 31 to 56Gy; for most of the patients it stayed within 35-40Gy range. If the primary tumour was located in the upper third of vagina, vaginal colpostat was used together with intrauterine applicator.
Fifteen (9.9%) of 22 IVA 0 stage PIVC patients were advised intracavitary brachytherapy (as in case of I 0 and III 0 stage) in combination with external radiotherapy; 7 (4.6%) patients, for whom it was technically not possible to perform intracavitary brachytherapy due to the extent of neoplastic disease in vagina, were treated with external radiation therapy alone.
In total, 127 (83.5%) patients received external radiotherapy treatment: 58 (45.7%) were irradiated with Co-60 beams and the remaining 69 (54.3%) with 10MV or 6MV linac photon beams.
Patients were treated with four external beams: anterior field, posterior field and two opposite lateral fields (so called box technique).
AP-PA fields covered the area from the lower edge of obturator foramens up to L4-L5 junction level with lateral boundaries extending 1-1.5cm sideways outside the pelvic brim. Lateral fields were limited in the anterior direction by the pubic symphysis.
Entry field size was 15x15cm to 15x18cm for AP-PA fields, and 15x8cm to 15x10cm for lateral fields. Pelvis minor area determined this way was irradiated with daily dose of 2Gy to total dose of 50Gy in 25 fractions within 5-week-period.
Tumour dose was calculated at the intersection of AP-PA and lateral fields axes. It was assumed that all the beams had equal dose contribution of 12.5Gy. All the fields were irradiated during one session a day. Patients with primary tumour in the lower third of vagina were advised elective inguinal irradiation.
Four patients with histopathology confirmed PIVC metastasis in inguinal lymph nodes were given additional 15-20Gy dose ("boost") to that area using smaller fields of 15MeV electron beams. Seven IVA 0 stage PIVC patients treated with external radiotherapy alone were given 15-20Gy boost using "shrinking-field technique" up to total dose of 65-70Gy.
Of the 152 patients in the investigated group, 70 (46.1%) had 5-year disease-free survival (DFS), 74 (48.7%) died of PIVC during the 5-year follow-up period, and 8 (5.2%) died of other cause. Detailed analysis of treatment results has been presented in earlier work, "Prognostic factors for vaginal carcinoma patients".
Treatment course and complications
All the patients of the investigated group developed symptoms of postradiation reaction with 69 (45.4%) cases of considerable severity, mainly including loose stool, diarrhoea, abdominal pain, pollakiuria, difficulty and pain during micturition, purulent or bloody-and-mucoid vaginal discharge. Advised treatment involved diet control, administration of antidiarrhoeic drugs, analgesics and antibacterial drugs, vagina irrigation, etc. In definite majority of the patients (94.7%) the symptoms subsided within 2-3 months from the completion of radiotherapy; in several cases it lasted a little longer. Table II presents the course of radiotherapy treatment in the investigated group of patients. Table II suggest that the radiotherapy tolerance in the investigated group of patients was good. Hundred forty six (96.1%) patients completed full planned radiotherapy. Six (3.9%) patients completed planned brachytherapy, but were not given full planned external radiotherapy dose due to condition deterioration (2 patients), exacerbation of accompanying disease symptoms (3 patients) and further radiotherapy refusal (1 patient). In all these cases patients received at least 2/3 of the planned external radiotherapy dose.
Data presented in
Late complications of radiation therapy were observed in 21 (13.8%) patients of the investigated group. Table III [20] .
Late radiotherapy complications in the investigated group included G1 complications observed in 3 (2%) patients, G2 in 12 (7.9%) patients, and G3 in 6 (3.9%) patients. There were no G4 complications in the group so that none of the patients died directly of radiotherapy complications.
Eleven patients had rectal complications in the form of recto-vaginal fistula (G3a) -5 patients, chronic rectal bleeding periodically requiring hospitalization and blood transfusion (G2a) -3 patients, and pain and tenesmus associated with necrotic rectal ulceration (G2b) -3 patients.
Bladder complications were observed in 5 patients: vesicovaginal fistula (G3d) in 1 patient, hematuria periodically requiring Total 152 100.0
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hospitalization and blood transfusion as well as intensive antibacterial treatment (G3a) in 3 patients, and occasional incontinence (G1c) in 1 patient. Vagina complications observed in 5 patients included vaginal narrowing and shortening to more than half the original dimensions (G2a) -2 cases, symptomatic vulval fibrosis (G2c) -1 case, and vaginal narrowing and shortening to less than half the original dimensions (G1b) -2 cases.
Late radiotherapy complications occurred in the investigated group of patients 7 to 34 months after the treatment completion with 2/3 of the cases manifesting after 10 to 13 months.
All the G1 and G2 complications were managed with conservative therapy. Chronic rectal bleeding and hematuria were treated with blood transfusion, bladder infusions and enemas of agents controlling bleeding and accelerating ulceration healing, antibiotic treatment, analgesic and anti-inflammatory drugs; tenesmus patients were advised dietetic and antidiarrhoeic treatment. Inflammatory condition in vagina was reduced by general anti-inflammatory treatment and regular vagina irrigation. Attempts were made to prevent vaginal narrowing by regular vagina dilatation as well as local application of oestrogen creams or pentoxifylline with vitamin E. In most of the cases the conservative treatment proved to be effective and the symptoms subsided within few months or were considerably reduced (e.g. vagina narrowing).
Six patients in the group developed fistulas (5 cases of 3a grade recto-vaginal fistula and 1 case of 3d grade vesico-vaginal fistula). Three of these patients (III 0 and IVA 0 stage PIVC) died of locoregional failure (2 patients) and simultaneous distant metastasis (1 patient). Remaining 2 patients with recto-vaginal fistula underwent surgical treatment; one of them was diseasefree for 5 years, the other died 4 years after the radiotherapy was started and 18 months after the surgery due to locoregional recurrence.
Cox multifactoral regression analysis did not result in any statistically significant, independent prognostic factors either for acute postradiation reaction or late radiotherapy complications.
Discussion
All 152 patients of the investigated group developed symptoms of postradiation reaction with 69 (45.4%) cases of considerable intensity, which is consistent with other reports [2, 4, 22, [26] [27] [28] [29] .
In some patients ineffective repair process is responsible for late radiotherapy complications. In vagina, fibrosis, vaginal narrowing and/or shortening, vaginal dryness, elasticity loss, ulceration and even necrosis are observed. Postradiation rectointestinal complications include persistent and bothersome diarrhoea, relapsing inflammations, chronic bleeding, and intestinal and rectal stenosis; complications in bladder and ureter include relapsing bladder mucosistis, chronic dysuria, hematuria and ureteral stenosis with progressive hydronephrosis.
The most severe radiotherapy complications observed in PIVC patients include complete vaginal stenosis, vaginal necrosis, small bowel obstruction, intestinal perforation, and recto-vaginal, vesico-vaginal or uretero-vaginal fistula [1, 2, 4-6, 8, 9, 11, 16, 17, 19, 21, 22, 24, 25, 27, 28, 30, 31] .
As reported in the literature, severe radiotherapy complications develop in 5-19% of PIVC patients [2-5, 8-11, 15-17, 19, 21, 24, 25, 27, 28, 30, 32] . In the investigated group, severe complications occurred in 11.8% of patients.
One of the most frequent late radiotherapy complications in PIVC patients is various grade vaginal stenosis reported in the literature in 10-50% of the patients [2, 22, [33] [34] [35] [36] [37] . Obviously, much increased (G3) vagina narrowing is significantly rarer in larger groups, e.g. in 55-patient group analyzed by Lian et al. it was observed in 3 cases i.e. in 5.5% of the patients [5] . In the group analyzed in this work vagina narrowing and shortening of a higher grade (G2a) had 2 (1.3%) patients and of a lower grade (G1b) additional 2 patients. Vagina necrosis occurs rarely; Hegemann et al. reported 1 case in a 41-patient group, and Chyle et al. recorded 8 cases in presented group of 301 patients [4, 11] . Single necrotic loci in vaginal mucosa are more frequent and reported in the literature in 4-15% of PIVC patients treated with brachytherapy combined with external radiation therapy [2, 34, 38] . In the investigated group, there were no cases of postradiation necrosis in vagina.
Developing a fistula or fistulas (recto-vaginal, vesicovaginal, uretero-vaginal or cutaneous-vaginal) is a severe radiotherapy complication and its frequency is reported in the literature as 1-8% [5, 26, 34, 36, 39] . In the investigated group there were 6 cases of postradiation fistula: 5 recto-vaginal and 1 vesico-vaginal, which constituted 3.9% of the patients.
In the investigated group there were 3 cases of a severe chronic rectal bleeding and 3 cases of pain and tenesmus associated with necrotic rectal ulceration, which constituted 3.9% of patients. Though, there were no cases of severe intestinal complications requiring surgical treatment, i.e. extensive ulceration, perforation or high grade stenosis, reported by other researchers [11, 26, 30] .
Some authors emphasize the relation between severe postradiation complications occurrence and initial stage of neoplastic disease; there is no doubt that for III 0 and IV 0 stage PIVC patients who were given radical radiotherapy the risk of these complications is much higher [11, 21, 26, 30, 33] .
The literature reports much more factors potentially increasing late postradiation complication risk in PIVC patients such as smoking, earlier surgical treatment, inflammations in pelvic area, immunosuppression conditions, low body weight, advanced age, accompanying diseases (diabetes, hypertension) etc. Their impact has not been commonly proved, though it has been observed by some researchers [17, 21, 26, 30] . 
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Mock et al. have analyzed HDR brachytherapy treatment administered alone or in combination with external radiation therapy and found no pre-therapeutic factors affecting the frequency of late severe postradiation complication occurrence, as also did de Crevoisier et al. and authors of this work [2, 6] .
Late radiotherapy complications generally develop 6 months to 2 years after the radiation treatment with the average of 1 year; more than 95% of the complications occur within the first 5 years, however, the complications may occur even 16 years after the treatment [29, 39] . Late radiotherapy complications occurred in the investigated group of patients 7 to 34 months after the treatment completion with 2/3 of the cases manifesting after 10 to 13 months.
Decrease in the frequency of late postradiation complications occurrence in PIVC patients might probably be achieved by the introduction of modern radiotherapy techniques, particularly IMRT [17, 40, 41] .
Conclusions
Radiation therapy is effective and well-tolerated therapeutic management for PIVC patients. Late radiotherapy complications occur in several per cent of the cases, and severe complications, mainly of grade 3, only in few per cent of the patients. Providing appropriate conservative or surgical treatment (fistulas), the complications are not life-threatening for the patients.
